2016 American Transplant Congress
Subtype-Compatible (A2/A2B–>B) Transplantation Under KAS Increases Access 3-Fold for Blood Type B Patients, yet Very Few Candidates Are Listed as Eligible.
Background: Prior to the new kidney allocation system (KAS; 12/4/14), 8 OPOs participated in a voluntary policy variance permitting allocation of kidneys from subtype “A2”…2016 American Transplant Congress
Safety of a Short (One-Year) Waiting Time in Kidney Transplant Candidates Treated for Cancer.
In Norway, a one-year waiting time free of cancer recurrence is required before kidney transplantation. To provide an updated, large-scale assessment of this practice, the…2016 American Transplant Congress
Analysis of FSGS (Focal Segmental Glomerulosclerosis) Recurrence After Renal Transplantation.
Nephrology-Division, Hospital do Rim - UNIFESP, São Paulo, Brazil.
Purpose: To describe clinical-laboratorial profile and outcome of patients diagnosed with recurrent FSGS submitted to plasmapheresis.Methods: Retrospective single-center cohort study including all patients with recurrent…2016 American Transplant Congress
Does DCD Donor Time-to-Death After Withdrawal of Support Affect Recipient Outcomes? Implications of Time-to-Death at a High-Volume Center in the United States.
Surgery, University of Wisconsin, Madison, WI.
Introduction: Donation after circulatory death (DCD) kidneys represent 15% of the deceased donor kidneys transplanted in the United States. A majority of transplant centers will…2016 American Transplant Congress
Effect of Complement Inhibition Therapy (Eculizumab) in Patients with C1q-Binding Donor-Specific Anti-HLA Antibodies: A Molecular Appraisal.
Complement-binding anti-HLA DSA have demonstrated higher rejection rate and decreased allograft outcome. We investigated the effect of terminal complement inhibition (Eculizumab) in a cohort of…2016 American Transplant Congress
Potential Kidney Donors with Asymptomatic Micorsocpic Hematuria: Histopathological Findings & Outcomes.
Background: Microscopic hematuria is not uncommon in potential kidney donors. After excluding urological causes, most of these donors require kidney biopsy to exclude glomerular lesions.…2016 American Transplant Congress
mRNA Expression of BAFF and APRIL Receptors Increases in Acute Rejection in Kidney Transplant Recipients.
Introduction:BAFF and APRIL are known survival and growth of B- cells.BAFF and APRIL share two receptors i-TACI and ii- BCMA. Additionally, BAFF has strong affinity…2016 American Transplant Congress
Delayed Graft Function (DGF) Does Not Accelerate Progression of Fibrosis During the First Year After Deceased Donor Kidney Transplantation.
BackgroundOur aim was to study the impact of DGF on the progression of interstitial fibrosis during the first post-transplant year.MethodsWe included all patients who received…2016 American Transplant Congress
Standardized Pre-Implantation Kidney Biopsies of Expanded Criteria Donors to Improve the Kidney Donor Profile Index (KDPI) for the Evaluation of Marginal Donors.
There is no consensus of selection criteria used to allocate renal transplants from expanded criteria donors (ECD). The Kidney Donor Profile Index (KDPI) has been…2016 American Transplant Congress
Eary Use of Statins Associated with Improved Death-Censored Graft Survival Following Kidney Transplant.
Purpose: The impacts of statin therapy on patient and graft outcomes after kidney transplantation (KT) are controversial.Methods: We performed a retrospective cohort study of adult…
- « Previous Page
- 1
- …
- 78
- 79
- 80
- 81
- 82
- …
- 180
- Next Page »